What do 443 global life science researchers really think about AI? In this on-demand session, BioInfo analyst Danyi Wu, Ph.D. unpacks the latest data on adoption trends, trust barriers, and commercial opportunities from the 2026…

AI models trained on public data can only see 15% of what actually drives life sciences strategy. The organizations that win will be the ones who make their proprietary archives visible first.

Theranostics is moving beyond oncology — and IMV’s latest PET Census data shows exactly where adoption is shifting. Download the free snapshot pdf.

In vivo CAR-T is moving from concept to clinic and it’s redistributing analytical instrument demand in ways OEMs can’t afford to miss. SDi maps where the opportunity is shifting.

For more than a decade, CAR-T cell therapy has represented one of medicine’s most exciting frontiers, a technology capable of sending certain blood cancers into lasting remission after all other treatments have failed. Yet for…